Live feed08:00:00·344dPRReleasevia QuantisnowGilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income CountriesByQuantisnow·Wall Street's wire, on your screen.GILD· Gilead Sciences Inc.Health Care
